FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993078113> ?p ?o ?g. }

• W1993078113 endingPage "413" @default.
• W1993078113 startingPage "406" @default.
• W1993078113 abstract "Mylotarg (Wyeth-Ayerst Laboratories, St. Davids, PA) is the brand name for a calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) and has been approved recently for the treatment of a subset of elderly patients who have relapsed acute myeloid leukemia (AML). Mylotarg is associated with an incidence of approximately 20% Grade 3 or 4 hyperbilirubinemia and liver transaminitis in this patient population. Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy.The authors assessed the incidence of VOD in 119 patients who were receiving Mylotarg-containing non-SCT regimens. VOD was diagnosed through the use of standard Seattle and Baltimore criteria.A cohort of 119 (61 previously untreated, 58 with relapsed disease) patients with AML (92 patients), advanced myelodysplastic syndrome (25 patients), or chronic myeloid leukemia in blast phase (2 patients), received Mylotarg-based regimens. Fourteen (12%) developed VOD. The diagnosis of VOD was supported by histology in 2 patients and radiologic studies in a further 10 patients. Five (36%) of 14 patients with VOD had received no prior antileukemic cytotoxic therapy, including 2 patients who received single-agent Mylotarg therapy.Mylotarg was shown to be associated with the development of potentially fatal VOD in patients with leukemia who had not received SCT. VOD occurred when Mylotarg was used either as a single agent or when it was given with other cytotoxic agents. VOD occurred in Mylotarg-treated patients who had received no prior cytotoxic therapy. The current study concluded that risk factors for VOD should be assessed when considering Mylotarg therapy, and that attempts to avoid and treat VOD are warranted in patients who receive Mylotarg therapy." @default.
• W1993078113 created "2016-06-24" @default.
• W1993078113 creator A5030812509 @default.
• W1993078113 creator A5033626596 @default.
• W1993078113 creator A5038307470 @default.
• W1993078113 creator A5057920623 @default.
• W1993078113 creator A5058228575 @default.
• W1993078113 creator A5061026876 @default.
• W1993078113 creator A5061285204 @default.
• W1993078113 creator A5066360308 @default.
• W1993078113 creator A5083096702 @default.
• W1993078113 creator A5088389768 @default.
• W1993078113 creator A5090435894 @default.
• W1993078113 date "2001-01-01" @default.
• W1993078113 modified "2023-10-18" @default.
• W1993078113 title "Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation" @default.
• W1993078113 cites W143372461 @default.
• W1993078113 cites W1493475842 @default.
• W1993078113 cites W1518100747 @default.
• W1993078113 cites W1546367566 @default.
• W1993078113 cites W1966771497 @default.
• W1993078113 cites W1968731704 @default.
• W1993078113 cites W1970497431 @default.
• W1993078113 cites W1972172571 @default.
• W1993078113 cites W1972872787 @default.
• W1993078113 cites W1980251430 @default.
• W1993078113 cites W199387403 @default.
• W1993078113 cites W2005466120 @default.
• W1993078113 cites W2026710725 @default.
• W1993078113 cites W2030110774 @default.
• W1993078113 cites W2036351237 @default.
• W1993078113 cites W2036657484 @default.
• W1993078113 cites W2043873747 @default.
• W1993078113 cites W2054166646 @default.
• W1993078113 cites W2067209713 @default.
• W1993078113 cites W2068070915 @default.
• W1993078113 cites W2090598508 @default.
• W1993078113 cites W2090989822 @default.
• W1993078113 cites W2091082315 @default.
• W1993078113 cites W2094654602 @default.
• W1993078113 cites W2100752839 @default.
• W1993078113 cites W2108402832 @default.
• W1993078113 cites W2109782506 @default.
• W1993078113 cites W2111294836 @default.
• W1993078113 cites W2117062808 @default.
• W1993078113 cites W2145576215 @default.
• W1993078113 cites W2151348405 @default.
• W1993078113 cites W2160835020 @default.
• W1993078113 cites W2162929776 @default.
• W1993078113 cites W2326487196 @default.
• W1993078113 cites W3082443879 @default.
• W1993078113 cites W4252620072 @default.
• W1993078113 cites W73342896 @default.
• W1993078113 doi "https://doi.org/10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u" @default.
• W1993078113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11466696" @default.
• W1993078113 hasPublicationYear "2001" @default.
• W1993078113 type Work @default.
• W1993078113 sameAs 1993078113 @default.
• W1993078113 citedByCount "251" @default.
• W1993078113 countsByYear W19930781132012 @default.
• W1993078113 countsByYear W19930781132013 @default.
• W1993078113 countsByYear W19930781132014 @default.
• W1993078113 countsByYear W19930781132015 @default.
• W1993078113 countsByYear W19930781132016 @default.
• W1993078113 countsByYear W19930781132017 @default.
• W1993078113 countsByYear W19930781132018 @default.
• W1993078113 countsByYear W19930781132019 @default.
• W1993078113 countsByYear W19930781132020 @default.
• W1993078113 countsByYear W19930781132021 @default.
• W1993078113 countsByYear W19930781132022 @default.
• W1993078113 countsByYear W19930781132023 @default.
• W1993078113 crossrefType "journal-article" @default.
• W1993078113 hasAuthorship W1993078113A5030812509 @default.
• W1993078113 hasAuthorship W1993078113A5033626596 @default.
• W1993078113 hasAuthorship W1993078113A5038307470 @default.
• W1993078113 hasAuthorship W1993078113A5057920623 @default.
• W1993078113 hasAuthorship W1993078113A5058228575 @default.
• W1993078113 hasAuthorship W1993078113A5061026876 @default.
• W1993078113 hasAuthorship W1993078113A5061285204 @default.
• W1993078113 hasAuthorship W1993078113A5066360308 @default.
• W1993078113 hasAuthorship W1993078113A5083096702 @default.
• W1993078113 hasAuthorship W1993078113A5088389768 @default.
• W1993078113 hasAuthorship W1993078113A5090435894 @default.
• W1993078113 hasConcept C10205521 @default.
• W1993078113 hasConcept C126322002 @default.
• W1993078113 hasConcept C141071460 @default.
• W1993078113 hasConcept C176290653 @default.
• W1993078113 hasConcept C2777408962 @default.
• W1993078113 hasConcept C2778245361 @default.
• W1993078113 hasConcept C2778623314 @default.
• W1993078113 hasConcept C2778729363 @default.
• W1993078113 hasConcept C2780895475 @default.
• W1993078113 hasConcept C28328180 @default.
• W1993078113 hasConcept C2908647359 @default.
• W1993078113 hasConcept C2911091166 @default.
• W1993078113 hasConcept C54355233 @default.
• W1993078113 hasConcept C71924100 @default.
• W1993078113 hasConcept C86803240 @default.

• next